Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials
Salman R, Stephen J, Tierney J, Lewis S, Newby D, Parry-Jones A, White P, Connolly S, Benavente O, Dowlatshahi D, Cordonnier C, Viscoli C, Sheth K, Kamel H, Veltkamp R, Larsen K, Hofmeijer J, Kerkhoff H, Schreuder F, Shoamanesh A, Klijn C, van der Worp H, Haemorrhage C, Klug D, Casolla B, Puy L, Coffee M, Kuchcinski G, Labreuche J, van Nieuwenhuizen K, Algra A, van Gelder I, Kappelle L, Rinkel G, Schutgens R, Khatri P, Conwit R, Falcone G, Elm J, Anderson C, Song L, Pandian J, Hart R, Sharma M, Aref H, Tarhuni W, Fabregas J, Diener H, Endres M, Lemmens R, Kwon S, Lee B, Ameriso S, Milling T, Kasner S, Mikulik R, Xavier D, Beer R, Toni D, Eckstein J, Seiffge D, Ferro J, Tsivgoulis G, Sharma S, Wei-Liou C, Hohnloser S, Katsanos A, Bosch J, Healey J, Eikelboom J, Khaw A, Gladstone D, Pikula A, Coutts S, Smith E, Butcher K, Field T, Gioia L, Stapf C, Halse O, Ringleb P, Enzinger C, Sibon I, Montaner J, Caso V, Heuschmann P, Lip G, Haefeli W, Debette S, Dennis M, Wyller T, Rønning O, Eilertsen H, Ihle-Hansen H, Sandset E, Pennlert J, Glader E, Kruuse C, Wester P, Carlsson M, Forfang E. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology 2023, 22: 1140-1149. PMID: 37839434, DOI: 10.1016/s1474-4422(23)00315-0.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsSpontaneous intracranial hemorrhageOral anticoagulationCardiovascular eventsIntracranial hemorrhageAtrial fibrillationCardiovascular deathIndividual participant dataEligible trialsHazard ratioPrimary outcomeOngoing trialsFixed-effect inverse variance modelParticipant dataDirect oral anticoagulantsOral anticoagulant agentsCochrane systematic reviewCox regression modelPrevious intracranial hemorrhageInverse variance modelBritish Heart FoundationLong-term useSubgroup of participantsAntiplatelet monotherapyChange in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial
Anadani M, Turan T, Yaghi S, Spiotta A, Gory B, Sharma R, Sheth K, de Havenon A. Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial. Stroke 2023, 54: 921-927. PMID: 36876480, PMCID: PMC10050138, DOI: 10.1161/strokeaha.121.038202.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsAcute ischemic strokeIschemic strokeCardiovascular eventsPersistent smokersPersistent smokingSPS3 trialSmoking statusMyocardial infarctionMajor adverse cardiovascular events outcomesCardiovascular event outcomesMajor cardiovascular outcomesSubsequent cardiovascular eventsHistory of hypertensionRisk of strokeEnd of studyPost Hoc AnalysisPrior smokersRandomization armCardiovascular outcomesFormer smokersMonth 3Primary outcomeTotal cohort